Navigation Links
Breaking up Dangerous Clots,,

Dangerous blood clots that often develop after hip surgery can be reduced by 96 percent when patients receive about a month’s worth of treatment with a new type of blood thinner.
That’s the major finding from a new study published in this month’s Archives of Internal Medicine. Researchers from Sweden studied about 650 patients who were undergoing surgery for a hip fracture. About half received daily injections of the drug fondaparinux for between 19 and 23 days, while the other half received injections of a placebo.// All of the study participants had received six to eight days of treatment with the drug prior to beginning the study.

Researchers were able to measure outcomes in 428 of the patients. The incidence of postoperative venous thromboembolism, a form of deep vein clotting occurring after surgery, was 35 percent in the patients who received placebo vs. 1.4 percent in those who received fondaparinux.
There were no significant differences between the two groups in clinically significant bleeding, although those in the fondaparinux group did trend towards more major bleeding than those in the placebo group.

Finding ways to prevent dangerous blood clots in hip surgery patients is a major concern among doctors, because these patients are at highest risk of any surgical patients for the development of deep vein thromboss.
'"/>




Page: 1

Related medicine news :

1. Lung Cancer Surgeries Doesn’t Help Breaking Nicotine Dependence in Smoker
2. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
3. Dangerous food bacteria
4. Weight-loss Products Dangerous
5. Human Growth Hormone Found To be Dangerous For Human Use
6. Mixing Ginseng and Blood Thinners Might Be Dangerous
7. Swallowing Magnets Found To Be Dangerous for Kids
8. Vaginal Birth After C-section Dangerous For Both Mother And Baby
9. Listeria Food Poisoning Can Be Dangerous In Pregnant Women And Elderly
10. Wearing High Heels May Be Dangerous To Health
11. Sudden Rise in PSA Dangerous for men
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Breaking Dangerous Clots

(Date:12/5/2008)...fer heart problems, study says , , FRIDA...ly lung disease idiopathic pulmonary fibrosis (IPF...the disease to suffer severe cardiac events such a..., "If you look at them over time, people with IP... coronary syndrome, which is a greater increase th...
(Date:12/5/2008)...For many, city living is at its,finest during the...rther,glamorized by the festive parties, larger t...the joyful atmosphere. However, for many single ci...an emotionally trying time,filled with expectatio...,romance during the holidays have developed a neg...
(Date:12/5/2008)...- Norgine, the leading European specialty pharmace...anted Medical Futures the exclusive rights to mark... patent-protected product developed by Norgine for...tuations where a clean bowel is required. The prod...A by its partner Salix Pharmaceuticals. , In re...
(Date:12/5/2008).../ - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) announced... bid circular (the "Circular") to its shareholders...n" tender offer for up to US$50 million of common ...The Circular is being filed with the securities re...da. Under the terms of the tender offer, sharehold...
Breaking Medicine News(10 mins):Health News:Lung Disease Tied to Increased Risk for Cardiac Events 2Health News:Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures 2Health News:Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures 3Health News:Medical Futures partners with Norgine for MOVIPREP(R) in Canada 2Health News:QLT announces commencement of tender offer 2Health News:QLT announces commencement of tender offer 3Health News:QLT announces commencement of tender offer 4Health News:QLT announces commencement of tender offer 5
...t enabled gay men contact in Hong Kong has been in...according to a latest report. // Government healt... 2003 and November 2005, had HIV with similar gene...a Morning Post reported. The discovery was made w...
...ted among Americans has revealed that most of them... to a mere chance. The results of the study may no...rns about sex selection may be prevalent, leading ...und that only eight percent of people would use pr...
...t three feet tall and 37 pound in weight prior to... baby is her first child. // Eloysa Vasquez, conf...is imperfecta , a disorder that has rendered her b... had two miscarriages as well. During the pregnan...
...a mental health court, the first one of its kind i... motive to pick // out sober and non violent defen... them to languish in the jails. U.S. House Speake...,000 fund to help with administration of Kane Coun...
Other Medicine News:Health News:Americans Not Interested In Choosing Sex Of Child: Survey 2
(Date:12/3/2008).... Jude treatment alleviates long-term anemia and o...plications , , MEMPHIS, Tenn., Dec. 3 /PRN...nsert a corrective gene into mouse blood cells, sc...have alleviated sickle cell disease pathology. In ...ted mice showed essentially no difference from nor...
(Date:12/3/2008)..., Del., Dec. 3 Isogen, a contract ...erile filling, announced it has retained a,strate... to meet the global,biopharma demand for Isogen,s...d a successful first round series of capital,inve...acility in Q1 2009 to,deliver on the previously u...
(Date:12/3/2008)...EGO, Dec. 3 Vical Incorp...sive, binding letter of intent with EIP,Eczacibas...g of the company,s,Allovectin-7(R) immunotherapeu...epublic of Northern Cyprus. EIP has agreed to obta...ritory and to pay Vical upfront and milestone paym...
(Date:12/2/2008)...DGE, Mass., Dec. 2 Biopu...that the U.S. Naval Medical Research Center,(NMRC...n (FDA) a revised,investigational new drug (IND) ...mpany,s oxygen therapeutic Hemopure(R) [hemoglobin...ttlefield treatment of trauma patients. The study ...
Breaking Medicine Technology:Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Sage Software Healthcare Inc Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 7649 1Sage Software Healthcare Inc Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 7649 2Infant Development Program from EASY Baby Takes On the Sixty Percent Increase in Developmental Delays in Children 7647 1Infant Development Program from EASY Baby Takes On the Sixty Percent Increase in Developmental Delays in Children 7647 2Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 1Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 2Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 3Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 1Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 2Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 3
...PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - Gero...esentation of,research studies indicating that GRN...C)-based therapeutic for the treatment of,spinal c...mune,system., Presented by Geron scientist Ross Ok...ieties meeting in San Diego, the findings,could me...
...he Netherlands, June 11, 2007-Sugammadex - the nov...eveloped by Organon,the human healthcare business...pivotal trial a 9-12 times faster reversal of,neur...hout evidence,of post operative residual curarizat..., 2 The results of this pivotal Aurora trial,were ...
Other Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 3
...ne-125 implant is a combination of innovative desi...e visibility that makes BrachySource I-125 implant...You can be confident that every BrachySource I-125...rvices which is required by clinicians who must me...
...ne-125 implant is a combination of innovative desi...e visibility that makes BrachySource I-125 implant...You can be confident that every BrachySource I-125...rvices which is required by clinicians who must me...
The Double-J Closed Tip Ureteral Stent design revolutionized stenting over 15 years ago. Today, it remains one of the most widely used stents in the world. An exclusive ACMI design allows one-step in
...ternal drainage from the ureteropelvic junction to...e segment with no sideports prevents postoperative...ingrowth of the ureteral wall to the stent. Suppli...-time use. CAUTION: Periodic evaluation is advised...
Medicine Products: